Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AbbVie Inc. | IMBRUVICA (ibrutinib) | Diffuse large B-cell lymphoma (DLBCL) | Phase 3 | Trial Discontinued | oral | Oncology |
| AbbVie Inc. | IMBRUVICA (Ibrutinib) | Pancreatic cancer | Phase 3 | Trial Discontinued | oral | Oncology |
| AbbVie Inc. | SKYRIZI (risankizumab) vs COSENTYX (secukinumab) | Plaque psoriasis | Phase 3 | Data Released | SKYRIZI subcutaneous COSENTYX subcutaneous | Immunology: Anti-TNF |
| AbbVie Inc. | IMBRUVICA (Ibrutinib) and prednisone | Chronic Graft Versus Host Disease | Phase 3 | Ongoing | oral | Immunosuppressant |
| AbbVie Inc. | Tavapadon - (TEMPO-3) | Late Parkinson’s disease | Phase 3 | Data Released | Oral | Neurology |
| AbbVie Inc. | IMBRUVICA (Ibrutinib) + Venclexta - (SYMPATICO) | Mantle Cell Lymphoma | Phase 3 | Trial Planned | Oral | Oncology |
| AbbVie Inc. | IMBRUVICA (Ibrutinib) + VENCLEXTA (venetoclax) - (GLOW) | Chronic Lymphocytic Leukemia | Phase 3 | Data Released | Oral | Oncology |
| AbbVie Inc. | Venclexta (venetoclax) | Multiple myeloma | Phase 3 | Data Released | Oral | Oncology |
